S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women.
TL;DR: Moexipril is effective and well tolerated in the treatment of hypertensive, postmenopausal women and can safely be co-administered to hrt, and was well-tolerated by post menopausal women using hrt.
Journal ArticleDOI
Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence.
Mohammed Siddiqui,Eric Judd,Tanja Dudenbostel,Bin Zhang,Bin Zhang,Pankaj Gupta,Pankaj Gupta,Maciej Tomaszewski,Prashanth Patel,Prashanth Patel,Suzanne Oparil,David A. Calhoun +11 more
TL;DR: Findings indicate thatMasked uncontrolled hypertension in treated hypertensive patients is not attributable to antihypertensive medication nonadherence, and measurement of urinary drug and drug metabolite levels demonstrates a similarly high level of antihyertensive medication adherence in both MUCH and truly controlled hypertensive Patients.
Journal ArticleDOI
Increased Noradrenaline Content of Hypothalamic Nuclei in Association with Worsening of Hypertension after High Sodium Intake in the Young Spontaneously Hypertensive Rat
TL;DR: Observations lend support to the hypothesis that sodium and the sympathetic nervous system have synergistic effects in the pathogenesis of hypertension in the SHR.
Journal ArticleDOI
Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists.
TL;DR: Preliminary evidence suggests that olmesartan, an A II receptor blocker currently being evaluated for approval for clinical use, may provide antihypertensive efficacy that is superior to other members of the class.
Journal ArticleDOI
Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis
TL;DR: Irrespective of BMI, triple‐combination treatment resulted in greater LS mean reductions in seated diastolic BP (SeBP) and enabled a greater proportion of participants to reach BP goal vs the dual‐ Combination treatments at week 12.